98%
921
2 minutes
20
The quality of biological samples used in metabolomics research is significantly influenced by preanalytical factors, such as the timing of centrifugation and freezing. This study aimed to evaluate how preanalytical factors, like delays in centrifugation and freezing, affect metabolomics research. Blood samples, collected in various tube types, were subjected to controlled pre- and postcentrifugation delays. Metabolite levels were quantified using NMR spectroscopy and fitted in linear mixed models used to predict changes in metabolite concentrations over time. The results showed that some metabolites, such as lactic acid, were significantly affected by even short delays, while others remained stable for longer. The study introduced the concept of a "stability time point", marking when a metabolite's concentration changes by 20%. These predictive models were validated in a separate cohort. To apply these findings, the authors developed the PRIMA Panel, an open-source R Shiny tool. This tool allows researchers to assess the impact of preanalytical variations on their samples, predict metabolite stability, and generate performance reports. The PRIMA Panel was tested using samples from the Dresden Integrated Liquid Biobank, proving its utility in a real-world biobank setting. The study emphasizes the importance of tracking preanalytical factors to improve the reliability of metabolomics analyses. The PRIMA Panel is available online and for local deployment, providing a practical solution for quality control in metabolomics research. The results of the study underscore the importance of tracking preanalytical factors in biobanking. A versatile tool for assessing their impact on metabolic data is introduced, improving the reliability of future analyses.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11822734 | PMC |
http://dx.doi.org/10.1021/acs.analchem.4c04938 | DOI Listing |
J Crohns Colitis
July 2025
Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Background And Aims: The Food and Drug Administration (FDA) and European Medicines Agency (EMA) ensure the safety, efficacy, and security of treatments, including therapies for immune-mediated disorders such as inflammatory bowel disease (IBD). Their clinical trial guidelines aid sponsors in designing robust studies. While the EMA updated its guidelines for ulcerative colitis (UC) in 2018, the FDA issued new recommendations in April 2022.
View Article and Find Full Text PDFNat Rev Gastroenterol Hepatol
June 2025
Division of Gastroenterology and Gastrointestinal Endoscopy, IRCCS Ospedale San Raffaele, Università Vita-Salute San Raffaele, Milan, Italy.
Inflammatory bowel disease (IBD) is a growing global health challenge affecting more than 7 million people worldwide. With increasing prevalence across all age groups, including children and adolescents, IBD places substantial strain on health-care systems and society, resulting in high direct medical costs, lost productivity and reduced quality of life. Despite therapeutic advances, suboptimal disease control and delays in timely diagnosis and adequate treatment persist.
View Article and Find Full Text PDFJ Crohns Colitis
May 2025
Department of Pathophysiology and Transplantation, University of Milan, Milano, Italy.
Background And Aims: Inflammatory bowel disease (IBD) patients with Clostridioides difficile infection (CDI) are at increased risk of adverse outcomes. Data on fidaxomicin use in IBD remain scarce. We assessed the effectiveness and safety of fidaxomicin for CDI and its impact on IBD outcomes in a large international cohort.
View Article and Find Full Text PDFNPJ Breast Cancer
February 2025
University of Texas MD Anderson Cancer Center, Houston, USA.
Residual Cancer Burden (RCB) after neoadjuvant chemotherapy (NAC) is validated to predict event-free survival (EFS) in breast cancer but has not been studied for invasive lobular carcinoma (ILC). We studied patient-level data from a pooled cohort across 12 institutions. Associations between RCB index, class, and EFS were assessed in ILC and non-ILC with mixed effect Cox models and multivariable analyses.
View Article and Find Full Text PDFAnal Chem
February 2025
National Center for Tumor Diseases (NCT/UCC) Partner Site Dresden, Dresden 01307, Germany.
The quality of biological samples used in metabolomics research is significantly influenced by preanalytical factors, such as the timing of centrifugation and freezing. This study aimed to evaluate how preanalytical factors, like delays in centrifugation and freezing, affect metabolomics research. Blood samples, collected in various tube types, were subjected to controlled pre- and postcentrifugation delays.
View Article and Find Full Text PDF